Relay Therapeutics, Inc. Stock Price, News & Analysis

Relay Therapeutics, Inc. (Nasdaq: RLAY) is set to participate in two fireside chats, enhancing its visibility in the oncology and healthcare sectors. The events are scheduled for:

• Stifel 2023 Targeted Oncology Days on April 26, 2023, at 12:30 p.m. ET
• BofA Securities 2023 Health Care Conference on May 9, 2023, at 10:00 a.m. PT

Both discussions will be webcast live, accessible on Relay Therapeutics’ website, with archived replays available for 30 days post-event. Relay Therapeutics is a clinical-stage precision medicine company dedicated to revolutionizing drug discovery through innovative computational and experimental technologies, focusing on small molecule therapeutic discovery in oncology and genetic diseases.

Relay Therapeutics (Nasdaq: RLAY) announced promising initial clinical data for RLY-2608, an investigational allosteric PI3Kα inhibitor. The data demonstrated sustained target exposure of over 80% in mutant PI3Kα inhibition across various doses. Notably, no Grade 3 hyperglycemia, rash, or diarrhea, common treatment discontinuation events, were observed. A confirmed partial response was recorded in a breast cancer patient with extensive prior therapies. The ongoing ReDiscover trial, which began in December 2021, aims to evaluate this drug's safety and efficacy in patients with unresectable or metastatic solid tumors. Relay plans to initiate expansion cohorts in the second half of 2023. The results suggest RLY-2608 could transform treatment for patients with diverse PI3Kα mutations and improve the therapeutic index of PI3Kα inhibitors.

Relay Therapeutics (Nasdaq: RLAY) announced that initial clinical data from the ReDiscover trial for RLY-2608 will be presented at the AACR Annual Meeting 2023, scheduled for April 14-19, 2023. RLY-2608 targets mutant-selective inhibitors of PI3Kα, a kinase frequently mutated in cancers, impacting approximately 13% of patients with solid tumors. The company aims to discuss the data during a conference call after the presentation. The AACR will release clinical trial abstracts on March 14, 2023, and publish them on April 14, 2023.

Relay Therapeutics (Nasdaq: RLAY) will participate in two fireside chats this March. The first event is at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 10:30 a.m. ET, and the second is the Barclays Global Healthcare Conference on March 15, 2023, at 4:05 p.m. ET. Both events will be available for live webcasting on Relay Therapeutics’ website under the Events section. Archived replays will be accessible for up to 30 days after each chat. Relay Therapeutics is a clinical-stage precision medicine company focused on innovative drug discovery using its Dynamo™ platform.

Relay Therapeutics reported significant progress in its clinical trials, particularly RLY-4008 showing an 88% overall response rate at the pivotal dose and 63% across all doses in FGFR2-fusion cholangiocarcinoma patients. The company raised $300 million through a follow-on public offering, enhancing its financial position with approximately $1 billion in cash and equivalents expected to fund operations through 2025. They expanded their breast cancer portfolio with ongoing studies of RLY-2608 and disclosed three new preclinical programs, strengthening their pipeline. Relay anticipates crucial milestones in 2023, including completing pivotal cohort enrollment.

Relay Therapeutics (Nasdaq: RLAY) plans to report its fourth quarter and full year 2022 financial results and corporate highlights after market close on February 23, 2023. The company focuses on precision medicine by integrating computational and experimental technologies. Relay's Dynamo™ platform is designed to enhance drug discovery for challenging protein targets, particularly in oncology and genetic diseases. Relay aims to revolutionize small molecule therapeutic discovery in these areas, bringing transformative therapies to patients.

Relay Therapeutics (Nasdaq: RLAY) will participate in a fireside chat at the Guggenheim Healthcare Talks | Oncology Day on February 9, 2023, at 10:10 a.m. ET. The event will be streamed live and accessible on their website under the Events section. An archived replay will be available for 30 days post-presentation.

Relay Therapeutics is a clinical-stage precision medicine company focused on enhancing drug discovery through its innovative Dynamo™ platform, targeting oncology and genetic diseases. This cutting-edge approach combines computational and experimental technologies to develop impactful therapies for patients.

Relay Therapeutics (Nasdaq: RLAY) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 2:15 p.m. PT. The event will be webcast live, accessible via Relay Therapeutics' website under the News & Events section. An archived version will be available for 30 days post-event. Relay Therapeutics is a clinical-stage precision medicine company, innovating drug discovery using its Dynamo™ platform to target challenging protein targets, focusing on oncology and genetic diseases.